Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Thermo Adds New Member to SAB and More

Premium

Thermo Fisher Scientific said this week that it has appointed David Sabatini to its scientific advisory board.

Sabatini is a member of the Whitehead Institute for Biomedical Research, where he studies the basic mechanisms of cell growth. He has several affiliations with the Massachusetts Institute of Technology, serving as senior associate member of the Broad Institute, a member of the David H. Koch Institute for Integrative Cancer Research, and associate professor of biology. He is also an investigator at the Howard Hughes Medical Institute.


Pronota has appointed Carol Greve-Philips as its chief business officer and Els Hublous as chief financial officer.

Greve-Philips comes to Pronota from Genzyme, where she was VP of corporate development. She has also held sales, marketing, and management positions at Amersham, Chemsyn Science Laboratories, Watson Laboratories, and Toxikon.

Hubloux was previously at Capricorn Venture Partners, and has experience in clinical research and development, equity research, and venture capital investing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.